According to their data, IL-23R positivity was observed in 85–90% of adenocarcinomas and small cell carcinomas, while IL-23R positivity was only observed in 7.5% of squamous cell carcinomas (Li et al., 2013 supplementary Table 2). The gene discussed is IL23R; the disease is adenocarcinoma.